Solstice Oncology, founded in February, is emerging from stealth having already secured an investigational new drug application from the FDA for a Phase 2 trial of a CTLA-4 antibody purchased from China’s Harbour BioMed.
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
Annalee Armstrong